Kyverna Therapeutics, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-04-13: Disclosure Insider Trading Policies Proc Adopted; Period 2024-01-01..2024-12-31; Value Yes.
- 2026-04-13: Disclosure Award Timing MNPI Disclosure; Period 2024-01-01..2024-12-31; Value Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not ….
- 2026-04-13: Disclosure Award Timing How MNPI Considered; Period 2024-01-01..2024-12-31; Value we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on spe….
- 2026-04-13: Disclosure Award Timing MNPI Considered; Period 2024-01-01..2024-12-31; Value Yes.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-04-13 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2026-04-13 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not … | |
| 2026-04-13 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on spe… | |
| 2026-04-13 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | Yes | |
| 2026-04-13 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2026-03-26 10-K | Material Terms Of Trading Arrangement | 2025-10-01..2025-12-31 | 10b5-1 Trading Plan Activity Except as set forth below, during the fiscal quarter ended December 31, 2025, none of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that … | |
| 2026-03-26 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-26 10-K | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information, or MNPI. Although we do not h… | |
| 2026-03-26 10-K | Award Timing Method | 2025-01-01..2025-12-31 | Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on specific dates, we generally expect to issue equity awards to our executive officers annually in or before April of each year, and such awards are approved by the Compensation Co… | |
| 2026-03-26 10-K | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-26 10-K | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-03-26 10-K | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | In the year ended December 31, 2025, no options were granted to our NEOs within four business days prior to, or one business day following, the filing or furnishing of a periodic or current report by us that disclosed MNPI. | |
| 2026-03-26 10-K | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-12 10-Q | Material Terms Of Trading Arrangement | 2025-07-01..2025-09-30 | Name and Title of Director or Officer Date Adopted Type of Arrangement Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement Duration Karen Walker , Chief Technology Officer September 12, 2025 Rule 10b5-1 trading arrangement Up to 67,997 shares, plus 100% of net share… | |
| 2025-04-14 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-14 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not … | |
| 2025-04-14 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information (“MNPI”) . Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on spe… | |
| 2025-04-14 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-14 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-03-27 10-K | Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-27 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-27 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-27 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-27 10-K | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Equity Award Timing Procedures In accordance with Item 402(x) of Regulation S-K under the Securities Act, we are providing information regarding our procedures related to the grant of certain equity awards close in time to the release of material non-public information, or MNPI. Although we do not h… | |
| 2025-03-27 10-K | Award Timing Method | 2024-01-01..2024-12-31 | Although we do not have a formal policy, program or plan that requires us to award equity or equity-based compensation on specific dates, we generally expect to issue equity awards to our executive officers annually in the first fiscal quarter of each year , and such awards are approved by our Compe… | |
| 2025-03-27 10-K | Award Timing Predetermined | 2024-01-01..2024-12-31 | Yes | |
| 2025-03-27 10-K | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-03-27 10-K | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | In the year ended December 31, 2024, no options were granted to our NEOs within four business days prior to, or one business day following, the filing or furnishing of a periodic or current report by us that disclosed MNPI, other than a Current Report on Form 8-K disclosing the grant of an option aw… | |
| 2025-03-27 10-K | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | Yes | |
| 2025-03-27 10-K | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2024-11-13 10-Q | Material Terms Of Trading Arrangement | 2024-07-01..2024-09-30 | Name and Title of Director or Officer Date Adopted Type of Arrangement Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement Duration Karen Walker , Chief Technology Officer August 24, 2024 Rule 10b5-1 trading arrangement Up to 20,000 shares June 30, 2025 or such earl… | |
| 2024-08-12 10-Q | Material Terms Of Trading Arrangement | 2024-04-01..2024-06-30 | Name and Title of Director or Officer Date Adopted Type of Arrangement Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement Duration Dominic Borie , M.D., Ph.D., President, Research and Development * June 3, 2024 Rule 10b5-1 trading arrangement Up to 150,000 shares S… | |
| 2024-05-14 10-Q | Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-14 10-Q | Non Rule10b51Arr Adopted | 2024-01-01..2024-03-31 | No | |
| 2024-05-14 10-Q | Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No | |
| 2024-05-14 10-Q | Non Rule10b51Arr Terminated | 2024-01-01..2024-03-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |